Valneva : CMD confirmant les objectifs à CT/MT
>VLA15 : résultats de phase 3 attendus toujours fin 2025 - Valneva a tenu hier un CMD qui a été l’occasion de faire un point sur le différents actifs du portefeuille. Concernant VLA15 (lyme), la société confirme que le programme de phase 3 est sur les rails avec 100% des patients (9 000) ayant reçu les trois premières doses (primovaccination), permettant d’espérer des résultats fin 2025. En cas de résultats positifs la société déposera un dossier de demande d’AMM en 2...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.